ACXP - What's Going On With Acurx Pharmaceuticals Stock? | Benzinga
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) shares surged Monday. The company recently announced the successful completion and early discontinuation of the Ibezapolstat Phase 2b trial for the treatment of C. difficile infection.
What To Know: Last Monday, Acurx announced that it has discontinued the Phase 2b clinical trial of ibezapolstat due to success. The company will analyze the data and report topline efficacy results which will allow Acurx to advance it to Phase 3 clinical trials more quickly.
Robert ...